Here is some news about Athira Pharma:
- Phase 1 Trial Results: Athira Pharma reported favorable results from a Phase 1 clinical trial for its ALS drug candidate, ATH-1105. The trial demonstrated a strong safety profile, dose-proportional pharmacokinetics, and effective central nervous system (CNS) penetration in healthy volunteers12. These results reinforce the potential of ATH-1105 as a therapy targeting the neurotrophic hepatocyte growth factor (HGF) system.
- Strategic Focus: Following the failure of its previous lead candidate, fosgonimeton, Athira Pharma is exploring strategic alternatives to maximize shareholder value. The company has shifted its primary focus to ATH-1105, with plans to initiate clinical trials involving ALS patients by late 202534.
- Financial Position: Athira Pharma reported a net loss of $9.1 million for Q1 2025, with cash and investments at $36.7 million. The company has been cost-cutting and is navigating a critical juncture in its journey to bring novel therapies to market34.
- Stock Performance and Analysts' Views: The average target price for Athira Pharma Inc. (ATHA) is $0.40, with an upside of 50.04% from the current price of $0.271. The company's average brokerage recommendation is currently 3.0, indicating a "Hold" status1.
In conclusion, Athira Pharma has shown promising results with its ALS drug candidate ATH-1105, and the company is strategically pivoting its focus to this candidate after the discontinuation of its previous lead candidate. The company's financial position is cautious, and analysts have a positive outlook on the stock with a potential upside.
6/5/2025 01:53pm
